U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H16F3NO4
Molecular Weight 439.3833
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIPLASININ

SMILES

OC(=O)C(=O)C1=CN(CC2=CC=CC=C2)C3=CC=C(C=C13)C4=CC=C(OC(F)(F)F)C=C4

InChI

InChIKey=ODXQFEWQSHNQNI-UHFFFAOYSA-N
InChI=1S/C24H16F3NO4/c25-24(26,27)32-18-9-6-16(7-10-18)17-8-11-21-19(12-17)20(22(29)23(30)31)14-28(21)13-15-4-2-1-3-5-15/h1-12,14H,13H2,(H,30,31)

HIDE SMILES / InChI

Molecular Formula C24H16F3NO4
Molecular Weight 439.3833
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15214776 https://www.ncbi.nlm.nih.gov/pubmed/18392333 https://www.ncbi.nlm.nih.gov/pubmed/17276980

Tiplasinin (PAI-039) is an orally efficacious and selective plasminogen activator inhibitor-1 (PAI-1) inhibitor. Tiplasinin bound specifically to the active conformation of PAI-1 and exhibited reversible inactivation of PAI-1 in vitro. Tiplaxtinin exhibited in vivo oral efficacy in two different models of acute arterial thrombosis. The remarkable preclinical safety and metabolic stability profiles of tiplaxtinin led to advancing the compound to Phase-I clinical trial for Thrombosis, which was later discontinued.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Rodents: Phase 1 animals receiving low-dose (1 mg/kg oral gavage) Tiplasinin demonstrated a 52% decrease in thrombus weight (TW) versus controls with significant reductions in active plasma PAI-1, while the high-dose (10 mg/kg oral gavage) group demonstrated a 23% reduction in TW versus controls
Route of Administration: Oral
Tiplaxtinin inhibited rhPAI-1 activity measured in vitro by the fibrinolysis assay in a dose-dependent manner with IC50 22 uM
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:02:20 UTC 2023
Edited
by admin
on Fri Dec 15 16:02:20 UTC 2023
Record UNII
L396QIB983
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIPLASININ
INN   USAN  
USAN   INN  
Official Name English
TIPLASININ [USAN]
Common Name English
[1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl]oxoacetic acid
Systematic Name English
tiplasinin [INN]
Common Name English
PAI-039
Code English
Classification Tree Code System Code
NCI_THESAURUS C29750
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C77020
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
USAN
PP-16
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
FDA UNII
L396QIB983
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
CAS
393105-53-8
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
WIKIPEDIA
Tiplasinin
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
INN
8418
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
EPA CompTox
DTXSID30192548
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
SMS_ID
300000034376
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
ChEMBL
CHEMBL325441
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
PUBCHEM
6450819
Created by admin on Fri Dec 15 16:02:20 UTC 2023 , Edited by admin on Fri Dec 15 16:02:20 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY